![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Indivior Plc | INDV | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
1,001.00 | 958.00 | 1,013.00 | 987.00 | 961.50 |
Industry Sector |
---|
PHARMACEUTICALS & BIOTECHNOLOGY |
Top Posts |
---|
Posted at 24/7/2024 18:41 by waldron Casholaa24 Jul '24 - 18:35 - 4031 of 4031 0 0 0 |
Posted at 24/7/2024 18:35 by casholaa https://www.asktrade |
Posted at 09/7/2024 18:48 by casholaa I think that the last trade in the US 13:28:03 Traded price approx. US$10.255 = approx. £8.02 (delayed prices as it's about 13:49 now)Ticker should be U-INDV |
Posted at 09/7/2024 07:16 by la forge Richmond, VA, July 9, 2024 - Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its product portfolio and litigation. Indivior is:· Updating Q2 net revenue (NR) expectations and FY 2024 guidance to reflect continued adverse market dynamics impacting near-term SUBLOCADE NR growth as well as the initial commercial adoption of OPVEE; At the mid-point, the Group continues to expect strong YOY NR growth for SUBLOCADE of 25% and YOY adjusted operating income growth of 12% in FY 2024; · Reiterating its medium-term financial outlook for double-digit NR growth and operating margin expansion, based on its confidence in achieving its intermediate and peak NR goals for SUBLOCADE as well as peak NR expectations for OPVEE; · Discontinuing sales and marketing for PERSERIS due to expected adverse impacts from increased payor management of the category that crystalized in Q2 and that are expected to make the product no longer financially viable; and, · Reaching a settlement agreement with end payor plaintiffs in the Health Care Services Corp (HCSC) consolidated cases to resolve the litigation for $85m. |
Posted at 06/7/2024 17:48 by the grumpy old men [...]www.marketbeat.com/i |
Posted at 03/7/2024 15:00 by timmy11 if they announce a dividend, will shoot up , enough of buy backs |
Posted at 22/2/2024 13:19 by casholaa Fentanyl use is rising, so I take this to mean that the market for indv also increases. |
Posted at 20/12/2023 08:27 by adrian j boris Indivior PLC Indivior Settles Patent Dispute with Actavis (3885X)20/12/2023 7:00am UK Regulatory (RNS & others) Indivior (LSE:INDV) TIDMINDV RNS Number : 3885X Indivior PLC 20 December 2023 Indivior Settles Patent Dispute with Teva Subsidiary Actavis Richmond, VA and Slough UK, December 20, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, today announced that its subsidiaries Indivior Inc. and Indivior UK Limited (together, "Indivior") entered into a settlement agreement with Actavis Laboratories UT, Inc. ("Actavis"), a subsidiary of Teva Pharmaceuticals, to resolve patent disputes regarding Actavis's Abbreviated New Drug Application ("ANDA") for generic buprenorphine and naloxone sublingual film. Under the agreement, Indivior granted Actavis a license to U.S. Patent No. 11,135,216 that would enable Actavis to launch the generic film products identified in its ANDA in the United States no earlier than January 31, 2025, unless the unexpired patent claims are found invalid or unenforceable before that time in a final judicial decision. |
Posted at 05/12/2023 16:08 by waldron Indivior PLC INDV Prevails in Striking Claims in UK Litigation (7595V)05/12/2023 2:06pm UK Regulatory (RNS & others) Tuesday 5 December 2023 TIDMINDV RNS Number : 7595V Indivior Prevails in Striking Representative Claims from UK Shareholder Action Richmond, VA and Slough UK, December 5, 2023 - Indivior PLC (LSE/NASDAQ: INDV) , a leading addiction treatment company, announced that the High Court of Justice of England and Wales has issued a judgment striking out representative claims by Wirral Council as administering authority of Merseyside Pension fund ("Wirral") against Indivior under the Financial Services and Markets Act 2000 ("FSMA"). Wirral's suit was the first attempt by claimants to use representative proceedings for securities claims brought under Sections 90, 90A, and Schedule 10 of the FSMA. The proposed representative proceedings, if allowed, would permit a representative acting on behalf of unnamed claimants to attempt to prove a violation of law without proof of damages, in contrast to ordinary multi-party proceedings, which require proof of liability and damages for each claimant. In September 2022, Wirral had filed a representative claim generally asserting that Indivior violated the FSMA by making misleading or dishonest statements regarding an alleged fraudulent scheme to switch the market for its SUBOXONE (R) branded products in published information relating to securities. A similar claim was filed against Reckitt Benckiser. After hearing two days of argument in November 2023, the High Court on December 5 issued a judgment granting Indivior's and Reckitt Benckiser's applications to strike out the representative proceedings. The Court specifically found that it "would be unfair and unjust, and contrary to the overriding objective, to allow the Representative Proceedings to oust the jurisdiction of the Court to case manage the claims from the start." The Court's judgment may be found here . Wirral and other claimants separately had filed a multi-party action generally alleging the same claims, and levied similar allegations against Reckitt Benckiser Group PLC ("Reckitt Benckiser") in separate actions. Pursuant to the Court's judgment, the claim against Indivior may only proceed in those multi-party proceedings brought by the claimants named in those proceedings. Wirral may seek permission to appeal the Court's judgment. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 1,000 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/com This release is being made by Kathryn Hudson, Company Secretary Indivior PLC. Media Contacts : US Media : Cassie France-Kelly Vice President, Communications Indivior PLC Tel: 804-724-0327 UK Media : Teneo Tel: +44 207-353-4200 Investors and Analysts : Jason Thompson Vice President, Investor Relations Indivior PLC Tel: 804-402-7123 Tim Owens Director, Investor Relations Indivior PLC Tel: 804-263-3978 -ends- (END) Dow Jones Newswires December 05, 2023 09:06 ET (14:06 GMT) |
Posted at 09/11/2023 07:38 by ariane SLOUGH, United Kingdom and RICHMOND, Va., Nov. 9, 2023 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor presentation and webcast are available at www.indivior.com.Indivior (PRNewsfoto/Indivior The earnings release can be found at www.indivior.com/inv The investor presentation can be found at www.indivior.com/inv There will be a live webcast presentation at 13:00 BST (8:00 am EST) hosted by Mark Crossley, CEO. The details are below. Webcast link: Participants may access the presentation telephonically by registering with the following link: [...] |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions